Early clinical and pharmacokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL).

被引：2
|
作者：
Tarhini, Ahmad A. [1 ]
Land, S. [1 ]
Meisner, D. [1 ]
Pietragallo, L. [1 ]
Sulecki, M. [1 ]
Lim, F. [1 ]
Kiefer, Gauri J. [1 ]
Pinkerton, R. [1 ]
Obsom, J. [1 ]
Sukaly, S. [1 ]
Schaefer, P. M. [1 ]
Foon, Kenneth A. [1 ]
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2844.2844
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2844
引用
收藏
页码：805A / 805A
页数：1
相关论文
共 50 条
  • [21] Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia
    Short, Nicholas J.
    Keating, Michael J.
    Wierda, William G.
    Faderl, Stefan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Smith, Susan C.
    O'Brien, Susan M.
    CANCER, 2015, 121 (21) : 3869 - 3876
  • [22] Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
    Smolej, Lukas
    Spacek, Martin
    Brychtova, Yvona
    Belada, David
    Schwarz, Jiri
    Doubek, Michael
    Motyckova, Monika
    Cmunt, Eduard
    Rohon, Peter
    Klaskova, Katerina
    Kozak, Tomas
    BLOOD, 2010, 116 (21) : 1024 - 1025
  • [23] Low dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and refractory chronic lymphocytic leukemia
    Forconi, Francesco
    Toraldo, F.
    Sozzi, E.
    Lenoci, M.
    Fabbri, A.
    Gozzetti, A.
    Tassi, M.
    Raspadori, D.
    Lauria, Francesco
    BLOOD, 2007, 110 (11) : 612A - 612A
  • [24] Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL)
    Kovacs, G.
    Bahlo, J.
    Kluth, S.
    Fink, A. M.
    Cramer, P.
    von Tresckow, J.
    Maurer, C.
    Langerbeins, P.
    Gross-Opphoff-Mueller, C.
    Fischer, K.
    Wendtner, C. -M.
    Kreuzer, K. -A.
    Stilgenbauer, S.
    Hallek, M.
    Eichhorst, B.
    Goede, V.
    Oncology Research and Treatment, 2015, 38 : 91 - 91
  • [25] LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH UNTREATED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Forconi, F.
    Fabbri, A.
    Lenoci, M.
    Sozzi, E.
    Bocchia, M.
    Gozzetti, A.
    Tassi, M.
    Raspadori, D.
    Lauria, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 37 - 37
  • [26] Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia
    Foon, Kenneth A.
    Mehta, Dhaval
    Lentzsch, Suzanne
    Kropf, Patricia
    Marks, Stanley
    Lenzner, Diana
    Pietragallo, Louis
    Sulecki, Mathew
    Tarhini, Ahmad
    Boyiadzis, Michael
    BLOOD, 2012, 119 (13) : 3184 - 3185
  • [27] Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).
    Batty, Nicolas
    Badoux, Xavier C.
    Keating, Michael
    Lin, E.
    Lerner, Susan
    O'Brien, Susan
    Ferrajoli, Alessandra
    Kadia, Tapan
    Burger, Jan A.
    Faderl, Stefan
    Wierda, William G.
    BLOOD, 2009, 114 (22) : 1339 - 1340
  • [28] Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)
    Obrtlikova, Petra
    Jonasova, Anna
    Siskova, Magda
    Cmunt, Eduard
    Berkova, Adela
    Karban, Josef
    Svackova, Katerina
    Trneny, Marek
    BLOOD, 2012, 120 (21)
  • [29] Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience
    Fornecker, Luc-Matthieu
    Aurran-Schleinitz, Therese
    Michallet, Anne-Sophie
    Cazin, Bruno
    Dupuis, Jehan
    Guieze, Romain
    Dilhuydy, Marie-Sarah
    Zini, Jean-Marc
    Tomowiak, Cecile
    Lepretre, Stephane
    Cymbalista, Florence
    Brion, Annie
    Feugier, Pierre
    Leblond, Veronique
    Ysebaert, Loic
    BLOOD, 2012, 120 (21)
  • [30] Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL)
    Hornberger, J. C.
    Reyes, C. M.
    Shewade, A.
    Friedmann, M.
    Chan, L.
    Gutierrez, H.
    Satram-Hoang, S.
    Lerner, S.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345